How ever, the treatment of conditions involving physiolog ical mechanisms within the eye (e. g., glaucoma, diabetic retinopathy, cataracts, etc.) generally does require the permeation of topically applied ophthalmic drugs pri marily through the cornea.

It has been reported that benzalkonium chloride (BAC), bile salts, dimethyl sulfoxide (DMSO), ethylenediamine tetraace tate (EDTA) and l-dodecylazayl-cycloheptan-2-one (AZONE ®) enhance the corneal penetration of cer tain drugs.

A principal objective of the present invention is to provide for a method of enhancing drug delivery across mucus covered epithelial tissues, particularly those of the cornea, sclera and conjunctiva of humans and ani mals.

Higher order saccharides being covalently linked in any of a number of ways to form different isomeric structures include for example disaccharides such as maltose, cellobiose, sucrose and lactose and trisaccharides, such as raffmose.

The method of claim 6 wherein the composition comprises a viscosity enhancing polymer selected from the group consisting of: alginates, carrageenan, gar, karaya, locust beans, tragacanth, zanthan, carbomer, hydroxyethylcellulose, hydroxypropylcelluiose, hy droxypropylmethylcellulose, methylcellulose, polyvi nyl alcohol, polyvinyl pyrrolidone, carboxymethylcel lulose and agarose.

None had a history of cardiac or neurological disease.

The symptoms disappeared within 10 min in all but one subject, in whom intranasal irritation lasted for 25 min All subjects tolerated intranasal administration well and none found it to be painful.

Nonetheless. for ophthalmic uses, the previously described polymer concentration ranges are preferred.

Although many attempts have been made to safely and efficiently administer insulin, heparin and other macromolecular drugs by non- injectable routes, none have proved successful, and it has become apparent that the success of such ...

None of the six volunteers had local irritation of the nostrils 30 minutes after application, see table 2.

Edward T. Maggio 16870 W. Bernardo Drive Suite 390 San Diego, CA 92127 (hereinafter “Inventor(s)),” have invented certain new and useful improvements in Multimodal Particulate Formulations X for which Application No. 12/1 16 842 was filed on May 7, 2008 in the United States Patent Office; WHEREAS, Aegis Therapeutics, LLC, a limited liability company of the State of California, having a place of business at 16870 W. Bernardo Drive Suite 390, San Diego, CA 92127, (hereinafter “Assignee”), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said lnventor(s) (hereinafter collectively referred to as “Inventions”), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter “Patent(s)”) thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said lnventor(s) to have been received in full from said Assignee: Said lnventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in

fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

Such cooperation by said lnventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said lnventor(s) in providing such cooperation shall be paid for by said Assignee.

‘ Docket Number 35401-714201 IN WITNESS WHEREOF said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written Bygflb'; (fir; _'